Evidence map›Paper›PMID 40040726›Full record

ArticleFrontiers in oncology2025

Hodgkin lymphoma and Ewing sarcoma in pediatric patient carrying germline

Jakub Czarny, Dominika Galli, Agnieszka Wziątek, Agata Pastorczak, Bartosz Szmyd, Borys Przybyszewski, Anna Raciborska, Katarzyna Jończyk-Potoczna, Katarzyna Derwich

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jakub CzarnyFaculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Dominika GalliFaculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Agnieszka WziątekDepartment of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland.
Agata PastorczakDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Bartosz SzmydDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Borys PrzybyszewskiDepartment of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland.
Anna RaciborskaDepartment of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland.
Katarzyna Jończyk-PotocznaDepartment of Pediatric Radiology, Institute of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland.
Katarzyna DerwichDepartment of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germinal predisposition to malignancy is found in approximately 10% of oncological pediatric patients. As awareness of cancer risk factors associated with germline mutations increases, and with advancements in molecular techniques, more carefully selected patients are being tested. This approach enables the identification of new variants-both those that are clearly linked to tumorigenesis and candidates, which biological role needs to be functionally verified. Pathogenic variants within cancer-predisposing genes not only increase nearly eightfold the risk of secondary cancers but also may be associated with excessive toxicity of antineoplastic treatment. We present the case of a girl who developed classical Hodgkin lymphoma at the age of 8 years and secondary Ewing sarcoma at the age of 16 years. Her father was diagnosed with classical Hodgkin lymphoma at the age of 27 years. Genetic testing revealed the carriership of a germline heterozygous variant in the

Indexed as

Ewing’s sarcomagenetic predispositionHodgkin lymphomaPALB2tumorigenesis

Identifiers

PMID40040726
PMCPMC11876119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.